AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04400240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALLS
Description: The CALLS program will consist of 12 weeks of service delivery that will include one standard educational session by telephone or in-person meeting every week. The weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. Weekly content will be adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study, and further tailored according to prominent barriers to care in the scientific literature. Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6) Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation.
Study NCT03424954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EpxOstomy
Description: A 30-day post-operative automated text-messaging intervention for home monitoring of ileostomy output
Study NCT01500603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AdvanceXP Male sling device
Description: Patients will receive AdvanceXP retrourethral male sling (polypropylene mesh) implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route.
Study NCT01500603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pro-ACT balloon device
Description: Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
Study NCT04755166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral ridge augmentation
Study NCT02512601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulodexide
Description: Sulodexide (two capsules of Sulodexide 15 mg twice daily).
Study NCT02512601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression therapy
Description: Compression:~* With an orthosis: Compression 22-29 mmHg, length of 20 cm above the DVT area.~* With a bandage: 7-10 m long and 10 cm wide.~* Both strategies (orthosis vs bandage) are equally applicable.
Study NCT02609230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-201
Study NCT03976362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03976362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion
Study NCT02780856 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Imaging with the Calcivis System
Description: Following identification of both sound and unsound tooth surfaces, the teeth will be air-dried and a black \& white and luminescent image of each tooth taken. The images of each tooth will be overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
Study NCT02408003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose.
Study NCT02408003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone
Description: Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose.
Study NCT02959827 — intervention group
Intervention type: DRUG
Intervention: Iodinated contrast agents
Description: Use of iodine contrast agents and doses following the decision of the treating physician.
Study NCT03349424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin (Stilamin®) of 250μg/h, beginning within 3 hours (Visit 1) after the operation and lasting for 120 hours (each subject will receive the Stilamin of 30mg in total), and other postoperative conventional treatment protocol remain unchanged.
Study NCT01773551 — intervention group
Intervention type: OTHER
Intervention: Breast Density
Description: Development of a Quantitative Tissue Optical Index of Breast Density
Study NCT02123238 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: bed positioning
Study NCT01170455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: nasal intubation with macintosh laryngoscope after general anesthesia induction
Study NCT01170455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blind Intubation Device
Description: nasal intubation using Blind Intubation Device after general anesthesia induction
Study NCT01518166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
Study NCT01518166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
Study NCT01518166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: One single dose of 40 mg. Tablet
Study NCT01518166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: One single dose of 20 mg. Tablet
Study NCT02110329 — intervention group
Intervention type: GENETIC
Group type: NO_INTERVENTION
Intervention: evaluation of the recurrence rate according to molecular analysis
Study NCT04002284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib 12mg p.o. d1-14, 21days/cycle
Study NCT01518166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: griseofulvin
Description: One single dose of 500 mg. Tablet
Study NCT01518166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: One single dose of 1 mg. Tablet
Study NCT02192814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (200 mg/20 mL)
Description: Active Substance: Lacosamide~Pharmaceutical form: Solution for intravenous (iv) infusion~Concentration: adapted on concentration of oral dose in EP0009~Route of Administration: Drip infusion
Study NCT01286012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soluble Ferric Pyrophosphate in liquid bicarbonate
Description: Subjects will receive hemodialysis containing SFP at 2 µM (11 µg iron/dL of dialysate) at every dialysis session, for a total duration of 36 weeks.
Study NCT01286012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Conventional liquid bicarbonate
Description: Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
Study NCT01286012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erythrocyte Stimulating Agent (ESA)
Description: ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
Study NCT01286012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythrocyte Stimulating Agent (ESA)
Description: ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
Study NCT01286012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous (IV) Iron
Description: Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
Study NCT01286012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) Iron
Description: Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
Study NCT01453257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tailored Chemotherapy
Description: Patients will be treated with Folfox, Folfiri, Xelox or Xeliri and Cetuximab or Bevacizumab at usual doses tailored by:~K-ras native: Cetuximab. K-ras mutated: Bevacizumab Topoisomera 1 positive ( Topo-1): Irinotecan Topo-1 positive and ERCC-1 negative: oxaliplatin Topo-1 1 negative and ERCC-1 positive: investigator option Thimidylate synthase (TS) positive: No Fluoropyrimidines (FLP) TS negative: FLP Thimidylate phosphorylasa (TP) positive: Capecitabine TP negative: 5-FU
Study NCT00661622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 2,000 mcg injected into the liver every 4 weeks alternating between right or left lobe when tumors present throughout liver.
Study NCT00661622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
Study NCT00661622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embolization
Description: A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
Study NCT03438175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced communication by brochure, website and posters
Description: Several instruments to improve communication toward ICU patients' families were prepared for this study: a brochure of 12 pages, a website with 80 webpages, 8 posters for the waiting room, 1 sign for the ICU door. All these instruments are made to have more correct comprehension and to legitimize emotions of ICU patients' families.
Study NCT04053192 — intervention group
Intervention type: PROCEDURE
Intervention: BAV
Description: BAV
Study NCT04053192 — intervention group
Intervention type: PROCEDURE
Intervention: BAV + TAVR
Description: BAV + TAVR
Study NCT04053192 — intervention group
Intervention type: PROCEDURE
Intervention: SAVR
Description: Surgical aortic valve replacement (SAVR)
Study NCT04646798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty
Description: standard surgical approaches to repair of fractured elbows
Study NCT04646798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total elbow arthroplasty
Description: standard surgical approaches to repair of fractured elbows
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Additional medication to perioperative analgesic regimen in Group B
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Concentrate
Description: Additional medication to perioperative analgesic regimen to Group A
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT01240525 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CD4 DLI
Description: Patients will receive CD4 DLI between day 70 to 115 post transplant
Study NCT01240525 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No DLI
Description: Patients will not receive DLI as trial treatment
Study NCT04446130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine combined with HAAG Regimen
Description: Decitabine :20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine :1mg/d,d3\~16,intravenous infusion; Aclarubicin :10mg/d, d3\~d10, intravenous infusion; Cytarabine :10mg/m2,q12h,d3-16, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection
Study NCT01124123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: 20 mg oral tablet
Study NCT01124123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: 10 mg endovenous bilastine
Study NCT01534260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib, vorinostat and bortezomib
Description: Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
Study NCT04934709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active PBMT-sMF
Description: PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter. Six different sites of the knee extensor muscles (two medial, two lateral and two central points) were irradiated at the same time.
Study NCT04934709 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT-sMF
Description: Placebo PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter, but without any emission of therapeutic dose. Placebo PBMT-sMF was applied at six different sites of the knee extensor muscles (two medial, two lateral and two central points).
Study NCT02359045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1400147
Description: Treatment A
Study NCT02359045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D14000136
Description: Treatment B
Study NCT02359045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D14000137
Description: Treatment C
Study NCT02359045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epanova®
Description: Treatment D
Study NCT01077999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC = 2 , weekly.
Study NCT01077999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC = 2 , weekly.
Study NCT01077999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 50 mg/m2, weekly
Study NCT01077999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 50 mg/m2, weekly
Study NCT03976362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT03976362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT03976362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT03976362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study NCT03976362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion
Study NCT03976362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV infusion
Study NCT03976362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablets
Study NCT01077999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: panitumumab: 6mg/kg in weeks 1-3-5.
Study NCT01077999 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
Study NCT01077999 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
Study NCT00035607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa SC
Description: Subcutaneous (SC) injection of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
Study NCT00035607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa IV
Description: Intravenous administration of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
Study NCT02099344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artegraft
Description: Surgical placement of graft for hemodialysis access
Study NCT02099344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Propaten
Description: Surgical placement of graft for hemodialysis access
Study NCT02821299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laryngeal transplantation
Description: Laryngeal transplantation
Study NCT02823574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02823574 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Study NCT02663466 — intervention group
Intervention type: PROCEDURE
Intervention: erroneous off-midline closures
Description: All patients with pilonidal sinus recurrent disease following Limberg flap reconstruction in the recurrent group were examined by the authors in each study center and high resolution close-up photos of the patients' sacrococcygeal area were taken. These photos were then sent to all authors to asses and reach a collective decision to classify the erroneous off-midline closure technique and precisely measuring the distance between the flap border and the midline in the cleft. Same evaluation method was applied to the patients in nonrecurrent group. Following the completion of the assessments, all digital data of the patients were permanently deleted.
Study NCT04600076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BabyCenter site and the community group
Description: Participants will be asked to sign on to the BabyCenter community group for people with pregnancy or infant loss at least 3 times weekly for 6 weeks. Participants may choose to post or comment on the site but are not required to do so.
Study NCT02482194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: autologous transplantation of mesenchymal stem cells in spinal cord injury patients
Study NCT01588314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: gabapentin 100 mg capsules
Study NCT01588314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: compounded placebo capsules
Study NCT05752942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Student Intervention Matching System (SIMS)
Description: The Student Intervention Matching System (SIMS) is a pre-intervention matching assessment following the behavioral consultation model. The SIMS entails three steps to sequentially assess and then match students' individual characteristics to precise acquisition- or performance-based interventions. The 1st step corresponds to the problem identification stage in behavioral consultation. The 2nd step corresponds to the problem analysis stage of behavioral consultation.The 3rd step of SIMS corresponds to the implementation planning and evaluation stages of behavioral consultation.
Study NCT05752942 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group-based social skills training
Description: In the control condition, students received an unconditionally mismatched acquisition-based intervention (group-based social skills training). We selected group-based social skills training for four reasons: (a) participating schools had already been delivering it as their treatment-as-usual, (b) it is a common intervention in US schools, (c) it is only effective for students with acquisition needs, and (d) it represents a counterfactual contrast to the treatment condition because externalizing behaviors driven by performance needs will be reduced more by performance-based interventions than acquisition-based ones.
Study NCT03610945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Subjects will receive fluconazole once daily from Day 5 to Day 18
Study NCT03610945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: Subjects will receive quinidine twice daily from Day 5 to Day 12
Study NCT03610945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305
Description: Subjects will receive a single dose of EDP-305 on Day 1 and Day 14